The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Li H, Wang C, Guo C

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system.

Frontiers in pharmacology 2024;15;1385036 — 2024 — 1385036

Harrison PK, Boland HE, Aherne NJ, Palmieri DJ

An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report.

Case reports in oncology 2022 Jan-Apr;15;225-230 — 2022 Jan-Apr — 225-230

Sharma S, Kommineni K, Mehta SS, Singh H

Lorlatinib-Associated Acute Respiratory Distress Syndrome.

American journal of therapeutics 2020 Jan 24;; — 2020 Jan 24